Form 4: AXIM Biotechnologies Director Acquires Convertible Note
SEC Form 4 Filing
Peter O'Rourke, a director of AXIM Biotechnologies, acquired a convertible note worth $35,000, which can be converted into 3,500,000 shares of common stock.
Summary
- On March 15, 2024, Peter O'Rourke, a director of AXIM Biotechnologies, acquired a convertible note with a face value of $35,000.
- The note can be converted into 3,500,000 shares of AXIM Biotechnologies' common stock at a conversion price of $0.01 per share.
- Following the transaction, O'Rourke beneficially owns 4,500,000 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of a transaction. The acquisition of a convertible note by a director could be seen as a positive sign of confidence, but without further context, it's difficult to assess the overall impact.
Industry Context
This filing is a routine disclosure of a transaction by a company insider, which is common in the biotechnology industry. It provides transparency into the actions of company leadership.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of transaction: Peter O'Rourke acquired a convertible note. |
| 03/15/2024 | Date the convertible note is exercisable. |
| 03/18/2024 | Date of signature on the Form 4 filing. |
| 03/01/2034 | Expiration date of the convertible note. |
Keywords
Convertible Note, Director, Form 4, AXIM Biotechnologies, Beneficial Ownership, O'Rourke, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.